Abemaciclib (re-assessment: breast cancer, HR+, HER2- in combination with fulvestrant)


  • Active Substance: Abemaciclib
  • Name: Verzenios®
  • Therapeutic area: Breast cancer
  • Pharmaceutical company: Lilly Deutschland GmbH

Time table:

  • Start: 01.12.2021
  • Final decision by G-BA: 19.05.2022

Final decision:

  • Patients who have not yet received initial endocrine therapy: No additional benefit proved
  • Patients who have received initial endocrine therapy: Indication for a minor additional benefit